Stephen Neidle

Prof. Stephen Neidle

UCL School of Pharmacy, London, UK
orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2016 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SNStephen Neidle
Stephen Neidle

7 November 2017 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
RSRoberto Simone
Roberto Simone
RBRubika Balendra
Rubika Balendra
TMThomas G Moens
Thomas G Moens
EPElisavet Preza
Elisavet Preza
KWKatherine M Wilson
Katherine M Wilson
AIAdrian M Isaacs
Adrian M Isaacs
Intronic GGGGCC repeat expansions in C9orf72 are the most common known cause of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), which are characterised by degeneration of cortical and motor neurons, respectively. Repeat expansions have been proposed to cause disease by both the repeat RNA forming foci that sequester RNA‐binding proteins and through toxic dipeptide repeat proteins generated by repeat‐associated non‐ATG translation. GGGGCC repeat RNA folds into a G‐quadruplex secondary structure, and we investigated whether targeting this structure is a potential therapeutic strategy. We performed a screen that identified three structurally related small molecules that specifically stabilise GGGGCC repeat G‐quadruplex RNA. We investigated their effect in C9orf72 patient iPSC‐derived motor and cortical neurons and show that they significantly reduce RNA foci burden and the levels of dipeptide repeat proteins. Furthermore, they also reduce dipeptide repeat proteins and improve survival in vivo, in GGGGCC repeat‐expressing Drosophila. Therefore, small molecules that target GGGGCC repeat G‐quadruplexes can ameliorate the two key pathologies associated with C9orf72 FTD/ALS. These data provide proof of principle that targeting GGGGCC repeat G‐quadruplexes has therapeutic potential. Synopsis Small molecules targeting G‐quadruplex GGGGCC repeat RNA are effective at ameliorating disease phenotypes in C9orf72 patient neurons, and in vivo phenotypes in C9orf72 flies. Therefore, targeting expanded GGGGCC RNA could be an effective therapeutic strategy for C9orf72 ALS and FTD. FRET based screen identifies small molecules that specifically bind to C9orf72 repeat RNA G‐quadruplexes. Small molecules reduce RNA foci and dipeptide repeat proteins (DPRs) in C9orf72 patient neurons. G‐quadruplex GGGGCC binding small molecule improves survival and reduces levels of the toxic DPR poly‐GR in C9orf72 flies. Provides proof of principle for targeting GGGGCC RNA G‐quadruplexes in C9orf72 FTD/ALS.

1 June 2014 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
SOStephan A. Ohnmacht
Stephan A. Ohnmacht
SNStephen Neidle
Stephen Neidle

22 January 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
CMChiara Marchetti
Chiara Marchetti
KZKatherine G. Zyner
Katherine G. Zyner
SOStephan A. Ohnmacht
Stephan A. Ohnmacht
MRMathew Robson
Mathew Robson
SHShozeb Haider
Shozeb Haider
SNStephen Neidle
Stephen Neidle
Human pancreatic ductal adenocarcinoma (PDAC) involves the dysregulation of multiple signaling pathways. A novel approach to the treatment of PDAC is described, involving the targeting of cancer genes in PDAC pathways having over-representation of G-quadruplexes, using the trisubstituted naphthalene diimide quadruplex-binding compound 2,7-bis(3-morpholinopropyl)-4-((2-(pyrrolidin-1-yl)ethyl)amino)benzo[lmn][3,8]phenanthroline-1,3,6,8(2H,7H)-tetraone (CM03). This compound has been designed by computer modeling, is a potent inhibitor of cell growth in PDAC cell lines, and has anticancer activity in PDAC models, with a superior profile compared to gemcitabine, a commonly used therapy. Whole-transcriptome RNA-seq methodology has been used to analyze the effects of this quadruplex-binding small molecule on global gene expression. This has revealed the down-regulation of a large number of genes, rich in putative quadruplex elements and involved in essential pathways of PDAC survival, metastasis, and drug resistance. The changes produced by CM03 represent a global response to the complexity of human PDAC and may be applicable to other currently hard-to-treat cancers.

28 January 2012 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
DWDengguo Wei
Dengguo Wei
GPGary N. Parkinson
Gary N. Parkinson
ARAnthony P. Reszka
Anthony P. Reszka
SNStephen Neidle
Stephen Neidle
We report here the 1.62 Å crystal structure of an intramolecular quadruplex DNA formed from a sequence in the promoter region of the c-kit gene. This is the first reported crystal structure of a promoter quadruplex and the first observation of localized magnesium ions in a quadruplex structure. The structure reveals that potassium and magnesium ions have an unexpected yet significant structural role in stabilizing particular quadruplex loops and grooves that is distinct from but in addition to the role of potassium ions in the ion channel at the centre of all quadruplex structures. The analysis also shows how ions cluster together with structured water molecules to stabilize the quadruplex arrangement. This particular quadruplex has been previously studied by NMR methods, and the present X-ray structure is in accord with the earlier topology assignment. However, as well as the observations of potassium and magnesium ions, the crystal structure has revealed a highly significant difference in the dimensions of the large cleft in the structure, which is a plausible target for small molecules. This difference can be understood by the stabilizing role of structured water networks.

16 June 2015 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SOStephan A Ohnmacht
Stephan A Ohnmacht
CMChiara Marchetti
Chiara Marchetti
MGMekala Gunaratnam
Mekala Gunaratnam
RBRachael J Besser
Rachael J Besser
SHShozeb Haider
Shozeb Haider
SNStephen Neidle
Stephen Neidle
We report here that a tetra-substituted naphthalene-diimide derivative (MM41) has significant in vivo anti-tumour activity against the MIA PaCa-2 pancreatic cancer xenograft model. IV administration with a twice-weekly 15 mg/kg dose produces ca 80% tumour growth decrease in a group of tumour-bearing animals. Two animals survived tumour-free after 279 days. High levels of MM41 are rapidly transported into cell nuclei and were found to accumulate in the tumour. MM41 is a quadruplex-interactive compound which binds strongly to the quadruplexes encoded in the promoter sequences of the BCL-2 and k-RAS genes, both of which are dis-regulated in many human pancreatic cancers. Levels of BCL-2 were reduced by ca 40% in tumours from MM41-treated animals relative to controls, consistent with BCL-2 being a target for MM41. Molecular modelling suggests that MM41 binds to a BCL-2 quadruplex in a manner resembling that previously observed in co-crystal structures with human telomeric quadruplexes. This supports the concept that MM41 (and by implication other quadruplex-targeting small molecules) can bind to quadruplex-forming promoter regions in a number of genes and down-regulate their transcription. We suggest that quadruplexes within those master genes that are up-regulated drivers for particular cancers, may be selective targets for compounds such as MM41.